Nivolumab (Opdivo) for treatment of non-small cell lung cancer
HAYES, Inc.
Record ID 32016000791
English
Authors' recommendations:
Description of Technology: Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to programmed death (PD-1) pathway that is active in non-small cell lung cancer (NSCLC). Nivolumab inhibits PD-1, preventing it from interacting with its ligands and permitting activated T cells to attack tumor cells. Patient Population: Nivolumab is indicated for the treatment of metastatic NSCLC in patients with progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations should have disease progression on Food and Drug Administration (FDA)-approved therapy for these aberrations prior to receiving nivolumab.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=38426
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antineoplastic Agents, Immunological
- Nivolumab
- Carcinoma, Non-Small-Cell Lung
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.